Tenax Therapeutics Inc. Common Stock (TENX)
Stock · NASDAQ · Health Care
$1.37as of 10/16/2026
Price chart
Active signals
TENX Signal Track Record
How signals performed across all stocks →What TENX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +6.2% | 61% | September 3, 2026 |
| Bollinger Band BreakdownActive now | 20 | -1.8% | 45% | August 10, 2026 |
| Bollinger Band Breakout | 19 | -1.1% | 47% | June 23, 2026 |
| 200-Day Moving Average TouchActive now | 5 | +10.3% | 80% | June 3, 2026 |
| Any 20-session window (baseline) | -3.9% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TENX
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kin…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 14
- Website
- www.tenaxthera.com/
Fundamentals
- 1-day range
- $1.36$1.52
- Market cap
- $498.11M
- P/E (trailing)
- —
- P/E (forward)
- -0.91
- EPS (trailing)
- $-1.47
- Dividend yield
- —
- Beta
- 1.00
- Avg. volume
- 5.68M
- Dividend pay date
- February 26, 2018
How Tenax Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2015 annual results
Source: 10-K filed Jul 14, 2015 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Tenax Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TENXTenax Therapeutics Inc. Common Stock$1.36▼ 9.93%Market cap $498.11MP/E —$1.31$19.4
- BIOABioAge Labs Inc. Common Stock$4.84▼ 9.53%Market cap $500.98MP/E —$5.04$25.96
- OVIDOvid Therapeutics Inc. Common Stock$2.15▼ 4.87%Market cap $494.60MP/E —$1.18$3.11
- AQSTAquestive Therapeutics Inc. Common Stock$3.78▼ 6.90%Market cap $491.83MP/E —$2.93$7.55
- EOLSEvolus Inc. Common Stock$7.1▼ 6.21%Market cap $487.98MP/E —$3.86$9.31
- QTTBQ32 Bio Inc. Common Stock$7.52▼ 3.22%Market cap $482.18MP/E 7.95$1.91$23.57
- EVMNEvommune Inc. Common Stock$5.17▼ 12.82%Market cap $481.93MP/E —$6.52$33.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TENX Tenax Therapeutics Inc. Common Stock | $498.11M | — | $1.36 | ▼ 9.93% | $1.31$19.4 |
| BIOA BioAge Labs Inc. Common Stock | $500.98M | — | $4.84 | ▼ 9.53% | $5.04$25.96 |
| OVID Ovid Therapeutics Inc. Common Stock | $494.60M | — | $2.15 | ▼ 4.87% | $1.18$3.11 |
| AQST Aquestive Therapeutics Inc. Common Stock | $491.83M | — | $3.78 | ▼ 6.90% | $2.93$7.55 |
| EOLS Evolus Inc. Common Stock | $487.98M | — | $7.1 | ▼ 6.21% | $3.86$9.31 |
| QTTB Q32 Bio Inc. Common Stock | $482.18M | 7.95 | $7.52 | ▼ 3.22% | $1.91$23.57 |
| EVMN Evommune Inc. Common Stock | $481.93M | — | $5.17 | ▼ 12.82% | $6.52$33.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Doogan Declan · September 16, 2026 · Buy53.0K @ $1.92
- Giordano Christopher Thomas · September 15, 2026 · Buy4.8K @ $1.82
- Giordano Christopher Thomas · September 11, 2026 · Buy6.0K @ $1.88
- Thomas R. Staab II · September 11, 2026 · Buy5.7K @ $1.94
- ADAR1 Capital Management, LLC · September 3, 2026 · Buy900.0K @ $1.78
- ADAR1 Capital Management, LLC · September 2, 2026 · Buy187.7K @ $1.8
- ADAR1 Capital Management, LLC · September 1, 2026 · Buy179.1K @ $1.8
- ADAR1 Capital Management, LLC · August 31, 2026 · Buy403.6K @ $1.79
- ADAR1 Capital Management, LLC · August 24, 2026 · Buy107.4K @ $1.75
- ADAR1 Capital Management, LLC · August 21, 2026 · Buy716.4K @ $1.77
- ADAR1 Capital Management, LLC · August 20, 2026 · Buy202.1K @ $1.78
- Giordano Christopher Thomas · July 13, 2026 · Option Exercise8.5K @ $5.94
- Giordano Christopher Thomas · July 13, 2026 · Option Exercise219 @ $3.55
- Thomas R. Staab II · May 11, 2026 · Grant450.0K
- Thomas R. Staab II · May 11, 2026 · Grant10.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 21.21M
- Total value held
- $291.25M
- Institutional holders
- 76
- Unknown2.95M
- Unknown1.82M
- Unknown1.68M
- Unknown1.45M
- Unknown1.13M
- Unknown975.2K
- Unknown625.0K
- Unknown596.6K
- Unknown583.3K
- Unknown540.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting
Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting. Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.